Bioprospecting Marine Biodiversity for Drug Discovery
The oceans harbor immense biodiversity, making marine bioprospecting a promising frontier for drug discovery. The Blue Biotechnology market highlights how systematic exploration of marine species leads to the identification of novel bioactive compounds with pharmaceutical potential.
Bioprospecting involves collecting marine samples, isolating microorganisms, algae, or invertebrates, and screening their metabolites for therapeutic properties such as anticancer, antiviral, and anti-inflammatory effects. The chemical uniqueness of marine natural products arises from adaptations to extreme and competitive environments.
Notable successes include cytarabine and trabectedin, marine-derived drugs used in cancer therapy. Advances in high-throughput screening, metabolomics, and genomics accelerate the identification of promising candidates.
Sustainable harvesting and benefit-sharing frameworks are critical to preserving marine ecosystems while supporting innovation. Bioprospecting thus remains vital for expanding the pharmacopeia with marine-inspired drugs.